Accelerated progression of IDH mutant glioma after first recurrence

BACKGROUND: Isocitrate dehydrogenase (IDH) mutant gliomas are a distinct subtype, reflected in the World Health Organization (WHO) 2016 revised diagnostic criteria. To inform IDH-targeting trial design, we sought to characterize outcomes exclusively within IDH mutant gliomas. METHODS: We retrospecti...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: Miller, Julie J, Loebel, Franziska, Juratli, Tareq A, Tummala, Shilpa S, Williams, Erik A, Batchelor, Tracy T, Arrillaga-Romany, Isabel, Cahill, Daniel P
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2019
Pynciau:
Clinical Investigations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6502499/
https://ncbi.nlm.nih.gov/pubmed/30668823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz016
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg